- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04955106
Evaluation of the Sub Epidermal Moisture a Device for the Screening of Pressure Ulcer (RELIASEM) (RELIASEM)
Evaluation of the Relability and Validity of Device for the Screening of Early Pressure Ulcer in Hospitalization High-risk Patient, the Sub Epidermal Moisture During a Monocebtric Study
Study Overview
Detailed Description
The device that is the subject of this investigation is a diagnostic tool to detect the among of fluid in hypodermis to help to prevent the formation of pressure injuries. The Sub Epidermal Moister(SEM) Scanner, is a non invasive portable medical device use to complet the clinical jugement of clinician.
The study "RELIASEM" will study hospitalized patients with high risk of Pressure Injurieswith the next conditions:
For each patient 14 mesures: 6 on the sacrum, 4 on the right heel and 4 on the left heel. This set of measure will be realized 2 timesby 4 different evaluator. To will have been trained in the use of the SEM Scanner where as the other will be novice.
The main objective of this study is to determine on a risk population the intra- and inter-examiner reliability of the SEM Scanner
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Philippe Gallien, Doctor
- Phone Number: +33299295099
- Email: philippe.gallien@pole-Sthellier.com
Study Contact Backup
- Name: Jean-Paul Haeberle
- Phone Number: +33626742085
- Email: jean-paul.haeberle@arjo.com
Study Locations
-
-
Bretagne
-
Rennes, Bretagne, France, 35000
- Recruiting
- Pôle Saint-Hélier
-
Principal Investigator:
- Philippe Gallien, Doctor
-
Contact:
- Philippe GALLIEN, Doctor
- Phone Number: +33299295099
- Email: philippe.gallien@pole-sthelier.com
-
Contact:
- JEAN PAUL HAEBERLE
- Phone Number: +33626742085
- Email: jean-paul.haeberle@arjo.com
-
Sub-Investigator:
- Sandrine Robineau, Doctor
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged over 18
- Taken the full-hospital care in physical and rehabilitation Medicine
- Patient affiliated with a social security scheme
- In the case of curatorship, patient have read the patient information document and given his consent free and informed, in the presence of his/her curator
- In the case of guardianship, legal representative have to had read the legal representative information document for major placed under legal protection (under guardianship) and given his consent free and informed for the person for whom he is responsible (if the patient is agree),
Exclusion Criteria:
- Patient who objected his opposition during the exam
- Patient who have one or more presure ulcer on at list one of the measuring area
- Patient who has had a lower limb amputation
- Pregnant, post natal period or breastfeeding women,
- Person deprived of liberty by judicial or administrative decision
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: Sample for reliability
Reliability and validity of SEM Scanner : intra rater, inter rater and inter novice/trained 8(2 trained rater, 2 novice rater, each one performed twice)measured will be performed on each patient.
|
They will perform 2 sets of 3 measures (1 on sacrum, 1 on the right heel and 1 on the left heel)for each patients
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evaluation of the reliability of the SEM Scanner on a population in a rehabilitation center (experienced vs experienced)
Time Frame: immediately after the intervention
|
We will calculate the intra-class correlation coefficient (ICC) intra- and inter-evaluator (experienced vs experienced)
|
immediately after the intervention
|
|
Evaluation of the validity of the SEM Scanner on at risk population
Time Frame: immediately after the intervention
|
Intra-class correlation coefficient is the correlation coefficient between SEM Scanner measure and the norton scare
|
immediately after the intervention
|
|
Evaluation of the validity of the SEM Scanner on at risk population
Time Frame: During the evaluation 1 day assessed
|
The Norton scale will be used by the study :Norton ≥ 18 low or without risk, 14< Norton <18 medium risk, 12≤ Norton ≤14 high risk, Norton < 12 very high risk
|
During the evaluation 1 day assessed
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
valuation of the reliability of the SEM Scanner on a population at risk (experienced vs novice/ novice vs novice) will be calculated
Time Frame: immediately after the intervention
|
The intra-class correlation coefficient (ICC) intra- and inter- evaluator (experienced vs novice/novice vs novice) will be calculated
|
immediately after the intervention
|
|
Receiver Operating Characteristics (ROC)curve: Area under the Curve (AUC)
Time Frame: immediately after the intervention
|
AUC of the SEM Scanner for every cut of scores of the Norton score
|
immediately after the intervention
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2021-A00458-33
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.